Variation Biotechnologies Inc. to Present Positive Influenza Vaccine Data at the 49th Annual ICAAC Meeting

Published: Sep 11, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Variation Biotechnologies, Inc. (VBI), an emerging leader in the discovery and development of novel vaccines to fight infectious diseases, today announced that it plans to present positive results from a preclinical study of the company’s proprietary influenza vaccine at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), being held at the Moscone Convention Center in San Francisco, California.

Back to news